Premium
Ninety‐six‐hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients
Author(s) -
CALABRESE C.,
LIGUORI G.,
GABUSI V.,
GIONCHETTI P.,
RIZZELLO F.,
STRAFORINI G.,
BRUGNERA R.,
DI FEBO G.
Publication year - 2008
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2008.03733.x
Subject(s) - pantoprazole , lansoprazole , omeprazole , nerd , medicine , proton pump inhibitor , gastroenterology , reflux , gerd , esophageal ph monitoring , dosing , ambulatory , disease
Summary Background Comparative studies of proton pump inhibitors (PPIs) have revealed that acid reflux is influenced by PPI treatment, formulations and dosing regimens. Wireless pH capsules have circumvented some of the limitations of conventional catheter‐based pH testing with the additional advantage of 96‐h recording periods. Aim To clarify the effectiveness of intra‐oesophageal acid suppression by omeprazole, pantoprazole and lansoprazole in non‐erosive reflux disease patients through a 4‐day monitoring of oesophageal pH and related symptoms. Methods Twenty‐four patients with typical symptoms of gastro‐oesophageal reflux disease were enrolled and administered upper endoscopy and placement of a wireless pH capsule. Patients randomly received omeprazole, pantoprazole or lansoprazole for 3 days after the first 24 h. Symptom–reflux associations were expressed using the symptom index (SI). Results All patients completed the study. Significant decrease in acid exposure occurred on day 2 and in each successive day in all groups. Pantoprazole and omeprazole are more effective than lansoprazole at inducing a normalization of intra‐oesophageal acid exposure at days 2 and 3. Significant reduction in SI at day 2 was observed. Conclusions Four‐day ambulatory oesophageal pH monitoring is feasible and safe. Omeprazole, pantoprazole and lansoprazole have an equivalent potency for normalizing intra‐oesophageal acid exposure after 3 days of treatment in non‐erosive reflux disease patients.